puc-header

Tumor-Induced Cholesterol Efflux from Macrophages Drives IL-4 Mediated Reprogramming and Tumor Progression

40 Pages Posted: 14 Nov 2018 Publication Status: Under Review

See all articles by Pieter Goossens

Pieter Goossens

Aix Marseille Université - CNRS, INSERM, CIML; Maastricht University - Department of Pathology

Juan Rodriguez-Vita

Aix Marseille Université - CNRS, INSERM, CIML; German Cancer Research Center (DKFZ), Vascular Signaling and Cancer (A270)

Anders Etzerodt

Aix Marseille Université - CNRS, INSERM, CIML; Aarhus University - Department of Biomedicine

Marion Masse

Aix Marseille Université - CNRS, INSERM, CIML

Olivia Rastoin

Université Côte d'Azur - Institute for Research on Cancer and Aging of Nice (IRCAN)

Victoire Gouirand

Aix Marseille Université - CNRS, INSERM, CIML

Miranda Van Eck

Leiden University, Leiden Academic Centre for Drug Research, Division of BioTherapeutics

Thomas Ulas

University of Bonn, LIMES Institute, Genomics and Immunoregulation; German Center for Neurodegenerative Diseases (DZNE) - Platform for Single Cell Genomics and Epigenomics (PRECISE)

Olympia Papantonopoulou

University of Bonn, Life and Medical Sciences Institute (LIMES), Genomics & Immunoregulation

Magali Bebien

Aix Marseille Université - CNRS, INSERM, CIML

Martin Turner

The Babraham Institute - Laboratory of Lymphocyte Signaling and Development

Thien Phong Vu Manh

Aix Marseille Université - CNRS, INSERM, CIML

Marc Dalod

Aix Marseille Université - CNRS, INSERM, CIML

Nathalie Auphan-Anezin

Aix Marseille Université - CIML

Joachim L. Schultze

University of Bonn - Life and Medical Sciences Institute (LIMES)

Toby Lawrence

King’s College London - Centre for Inflammation Biology and Cancer Immunology

More...

Abstract

Tumor-associated macrophages (TAM) have been shown to have important roles in the malignant progression of various cancers. However, macrophages also posses intrinsic tumoricidal activity and can promote the activity of cytotoxic lymphocytes, but they rapidly adopt an alternative phenotype within tumors, associated with immune-suppression and trophic functions that support tumor growth. The mechanisms that promote TAM polarization in the tumor-microenvironment remain poorly understood, these mechanisms may represent important therapeutic targets to block the tumor-promoting functions of TAM and restore their anti-tumor potential. Here we have characterized TAM in a mouse model of metastatic ovarian cancer. We show that ovarian cancer cells promote membrane-cholesterol efflux and the depletion of lipid rafts from macrophages. Increased cholesterol efflux promoted IL-4 mediated reprogramming while inhibiting IFNγ-induced gene expression. These studies reveal an unexpected role for tumor-induced membrane-cholesterol efflux in driving the IL-4 signaling and the tumor-promoting functions of TAM, while rendering them refractory to pro-inflammatory stimuli. Thus, preventing cholesterol efflux in TAM could represent a novel therapeutic strategy to block pro-tumor functions and restore anti-tumor immunity.

Suggested Citation

Goossens, Pieter and Rodriguez-Vita, Juan and Etzerodt, Anders and Masse, Marion and Rastoin, Olivia and Gouirand, Victoire and Van Eck, Miranda and Ulas, Thomas and Papantonopoulou, Olympia and Bebien, Magali and Turner, Martin and Manh, Thien Phong Vu and Dalod, Marc and Auphan-Anezin, Nathalie and Schultze, Joachim L. and Lawrence, Toby, Tumor-Induced Cholesterol Efflux from Macrophages Drives IL-4 Mediated Reprogramming and Tumor Progression (November 13, 2018). Available at SSRN: https://ssrn.com/abstract=3283707 or http://dx.doi.org/10.2139/ssrn.3283707
This version of the paper has not been formally peer reviewed.

Pieter Goossens

Aix Marseille Université - CNRS, INSERM, CIML ( email )

Marseille
France

Maastricht University - Department of Pathology ( email )

Minderbroedersberg 4-6
6211 LK Maastricht
Netherlands

Juan Rodriguez-Vita

Aix Marseille Université - CNRS, INSERM, CIML

Marseille
France

German Cancer Research Center (DKFZ), Vascular Signaling and Cancer (A270)

Heidelberg
Germany

Anders Etzerodt

Aix Marseille Université - CNRS, INSERM, CIML

Marseille
France

Aarhus University - Department of Biomedicine

Aarhus
Denmark

Marion Masse

Aix Marseille Université - CNRS, INSERM, CIML

Marseille
France

Olivia Rastoin

Université Côte d'Azur - Institute for Research on Cancer and Aging of Nice (IRCAN)

France

Victoire Gouirand

Aix Marseille Université - CNRS, INSERM, CIML

Marseille
France

Miranda Van Eck

Leiden University, Leiden Academic Centre for Drug Research, Division of BioTherapeutics

Postbus 9500
Leiden, 2300 RA
Netherlands

Thomas Ulas

University of Bonn, LIMES Institute, Genomics and Immunoregulation

Bonn
Germany

German Center for Neurodegenerative Diseases (DZNE) - Platform for Single Cell Genomics and Epigenomics (PRECISE)

Bonn
Germany

Olympia Papantonopoulou

University of Bonn, Life and Medical Sciences Institute (LIMES), Genomics & Immunoregulation

Bonn
Germany

Magali Bebien

Aix Marseille Université - CNRS, INSERM, CIML

Marseille
France

Martin Turner

The Babraham Institute - Laboratory of Lymphocyte Signaling and Development

Cambridge
United Kingdom

Thien Phong Vu Manh

Aix Marseille Université - CNRS, INSERM, CIML

Marseille
France

Marc Dalod

Aix Marseille Université - CNRS, INSERM, CIML

Marseille
France

Nathalie Auphan-Anezin

Aix Marseille Université - CIML

Marseille
France

Joachim L. Schultze

University of Bonn - Life and Medical Sciences Institute (LIMES)

Bonn
Germany

Toby Lawrence (Contact Author)

King’s College London - Centre for Inflammation Biology and Cancer Immunology ( email )

Strand
London, WC2R 2LS
United Kingdom